Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria
about
A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 DiabetesConcentrated insulins: the new basal insulinsConcepts and clinical use of ultra-long basal insulinInsulin degludec and insulin aspart: novel insulins for the management of diabetes mellitusSafety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first-year report from JapanCardiovascular effects of basal insulinsBiosimilar insulins: guidance for data interpretation by clinicians and usersThe evolution of insulin glargine and its continuing contribution to diabetes careType 1 diabetesModern basal insulin analogs: An incomplete storyTreatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitorsPatient safety and minimizing risk with insulin administration - role of insulin degludecThe evidence base for diabetes technology: appropriate and inappropriate meta-analysisClinical utility of insulin and insulin analogs.Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes.Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data.Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data.Insulin degludec in Japanese patients with type 1 diabetes mellitus: A randomized controlled trial.Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.Insulin Degludec Aspart: The First Co-formulation of Insulin AnaloguesMedium-term effects of insulin degludec on patients with type 1 diabetes mellitus.Prediction of nocturnal hypoglycemia unawareness by fasting glucose levels or post-breakfast glucose fluctuations in patients with type 1 diabetes receiving insulin degludec: A pilot study.Can a new ultra-long-acting insulin analogue improve patient care? Investigating the potential role of insulin degludec.A review of the pharmacological properties of insulin degludec and their clinical relevance.Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinicalInsulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials.A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials.Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates.The beneficial effect of insulin degludec on nocturnal hypoglycaemia and insulin dose in type 1 diabetic patients: a systematic review and meta-analysis of randomised trials.Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes.Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia.Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study.Switching from Twice-Daily Basal Insulin Injections to Once-Daily Insulin Degludec Injection for Basal-Bolus Insulin Regimen in Japanese Patients with Type 1 Diabetes: A Pilot Study.Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state.Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.Design of non-standard insulin analogs for the treatment of diabetes mellitusInsulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)Efficacy and safety of insulin degludec in Japanese patients with type 1 and type 2 diabetes: 24-week results from the observational study in routine clinical practice.
P2860
Q26741647-08F15CC9-30C1-4253-9B14-6E09AC3F6381Q26750438-6E146158-A56B-41A7-A4FF-6ABBC1B5216EQ26770354-6651D968-A0D5-4805-A2BF-BDD689BEB3A3Q26777076-26840505-E2EF-46B5-93C5-561B36F68128Q26778763-38229764-892A-4AA9-88CF-A1D9154287F9Q26800249-7A5B5BA5-D4EB-498F-B37A-B4D897129BDDQ26992066-AD815CA1-45CA-42F6-AF40-B60266AFC2D5Q26999454-917927BC-29BD-4312-8E8D-62EF28F246C0Q27000491-181F15DB-14D9-4E22-8E4F-8906C6F137E8Q27015047-2FD350B5-5687-40D6-87FE-FA3E403F5341Q27021870-708D2268-19A8-4E30-AA36-6896F417E44BQ27025548-A9ED33D8-FEE4-42B2-A8CC-28E661972553Q30409804-019AEAEF-88FC-4FCA-A26E-CB351D492133Q30429358-2F5E54E4-E720-40AE-BF9A-035930E2A3BBQ31046934-961015BB-CABD-4E74-8898-394E719131F4Q31152059-E9CC2D80-4F37-4795-9874-1DE8669CE95DQ31154873-CF0BB77B-A7DA-402E-8F8F-906C57776648Q33603473-8F4706EE-288C-49EF-8B66-C0B437E1AB07Q33607759-B376DF6E-D96D-434D-B5D4-852BF855754AQ33785168-AA20F73C-3671-4C27-A8A7-4FC90DAB6081Q33804815-CBDE7DA3-BA74-4591-B0EE-E0A4F332AC42Q33879458-CAAB2162-3407-460F-B413-9B630ED75DC0Q34311240-0331E024-FC42-4C00-B735-6435BF20D4B4Q34436383-E0AF7444-1D7B-494C-934A-BF3299E1E1D9Q34543035-53A3D9CF-9429-46BC-A17C-64B4B562D4BDQ34691408-B96B0504-C9A2-41D7-B28F-CB0C9359BDA3Q34726423-357EE9E8-6E58-4260-AB5F-734239CD3719Q34981168-485F4B38-CEE0-4F3E-8686-6A94D4C18AD5Q35134731-33934B84-EB73-4895-B7D5-056F45DDE75EQ35457098-A7A24258-FABB-425E-88D9-F5BBF1C7FB73Q35549468-9CB7B2DF-52FC-471D-8A46-2D8A7ADC6552Q35630711-D626448F-F08C-4202-BCD6-BF36F95767E2Q35921474-5A063529-5EA6-4900-8659-5A90E939D7F1Q36076126-A111E88D-87A0-4F95-ACBA-162EDDDECDCEQ36103732-09E1E77F-F587-4A28-B9C5-2934983073E0Q36158944-57D4B64C-BB28-4AA3-B6D9-494F690D0B53Q36334638-BDD96CB5-75B9-45AD-A9E7-F0BE53223F8EQ36374363-98EE0312-2BC8-452F-9A90-F7583E226DC9Q36426912-FE925098-1086-4AC5-9CE6-65ABB5E7DE36Q36477634-C65F4369-490C-4A54-88B2-7CDC8EDA99A5
P2860
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Insulin degludec, an ultra-lon ...... to-target non-inferiority tria
@ast
Insulin degludec, an ultra-lon ...... to-target non-inferiority tria
@en
Insulin degludec, an ultra-lon ...... to-target non-inferiority tria
@nl
type
label
Insulin degludec, an ultra-lon ...... to-target non-inferiority tria
@ast
Insulin degludec, an ultra-lon ...... to-target non-inferiority tria
@en
Insulin degludec, an ultra-lon ...... to-target non-inferiority tria
@nl
prefLabel
Insulin degludec, an ultra-lon ...... to-target non-inferiority tria
@ast
Insulin degludec, an ultra-lon ...... to-target non-inferiority tria
@en
Insulin degludec, an ultra-lon ...... to-target non-inferiority tria
@nl
P2093
P50
P1433
P1476
Insulin degludec, an ultra-lon ...... to-target non-inferiority tria
@en
P2093
Ann Marie Ocampo Francisco
Areti Philotheou
BEGIN Basal-Bolus Type 1 Trial Investigators
Bruce Bode
David Russell-Jones
Eric Renard
Huiling Pei
Ludwig Merker
Miles Fisher
Satish Garg
P304
P356
10.1016/S0140-6736(12)60204-9
P407
P577
2012-04-01T00:00:00Z